Pulmonary hypertension — classification & diagnostic approach
PH group evaluation · Cardiac
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Pulmonary hypertension is a mean pulmonary artery pressure >20 mmHg with diverse causes grouped into five WHO categories. Accurate classification is essential because management diverges sharply — PAH-specific drugs help Group 1 but can harm patients with left-heart or lung disease.
Red flags
- Syncope on exertion
- Rapidly progressive right heart failure
- Resting hypoxaemia
- Signs of low cardiac output
- Rapid functional-class deterioration
Assessment
Differential diagnosis
- Group 1 — pulmonary arterial hypertension
- Group 2 — left-heart disease (commonest)
- Group 3 — lung disease/hypoxia
- Group 4 — chronic thromboembolic (CTEPH)
- Group 5 — miscellaneous/multifactorial
- Non-PH causes of breathlessness
Investigations
- Transthoracic echo to estimate PA pressure and RV function
- Right-heart catheterisation (gold standard for diagnosis and haemodynamics)
- V/Q scan to exclude CTEPH
- Pulmonary function tests and high-resolution CT for lung disease
- Connective-tissue, HIV and liver screens for PAH associations
- NT-proBNP and 6-minute walk for risk stratification
Management
- Confirm raised PA pressure on echocardiography and assess RV function
- Systematically exclude left-heart disease (Group 2) and lung disease (Group 3)
- Perform a V/Q scan in all patients to detect CTEPH (Group 4)
- Confirm precapillary PH and measure pulmonary vascular resistance at right-heart catheterisation
- Classify into the correct WHO group before any therapy decision
- Treat the underlying cause in Groups 2 and 3 rather than using PAH drugs
- Refer Group 1 (PAH) and Group 4 (CTEPH) to a specialist PH centre
- Risk-stratify PAH using multiparametric tools to guide initial combination therapy
- Avoid PAH-specific vasodilators in left-heart or significant lung disease
- Provide supportive care: diuretics, oxygen, supervised rehabilitation
- Counsel on pregnancy avoidance in PAH
- Arrange specialist long-term monitoring
Drugs & doses
Treatment is group-specific; PAH drugs are reserved for Group 1/4 in expert centres
Furosemide 20-80 mg PO/IV for right-heart congestion (all groups)
Oxygen therapy for hypoxaemia (Group 3)
Diuretics and GDMT for the underlying left-heart disease (Group 2)
Specialist PAH therapy examples: ambrisentan, tadalafil, selexipag (Group 1 only)
Disposition
Refer confirmed/suspected Group 1 or 4 PH to a specialist pulmonary hypertension centre. Manage Groups 2 and 3 by treating the underlying disease.
Complications & pitfalls
- Right ventricular failure and death
- Arrhythmia
- Harm from inappropriate vasodilator use in Group 2/3
- Haemoptysis (especially CTEPH)
- Hepatic congestion
Exam pearls
- Group 2 (left-heart disease) is by far the most common cause of PH
- PAH-specific drugs can cause pulmonary oedema if given in left-heart disease
- A V/Q scan is mandatory to avoid missing curable CTEPH
- Right-heart catheterisation is required to confirm the diagnosis and class
- Only expert centres should initiate PAH-targeted therapy
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.